Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...
Business Insider1mon
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the ...
Yahoo Finance6d
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
CRB-913 has a brain to plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant. The Company expects to dose the first participant in the ...
Nasdaq2mon
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...